MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
MiMedx Group, Inc. (NASDAQ:MDXG) shareholders would be excited to see that the share price has had a great month, posting a 27% gain and recovering from prior weakness. The last month tops off a massive increase of 237% in the last year.
MimedX Group, Inc.(纳斯达克股票代码:MDXG)股东会很高兴看到股价表现良好,上涨了27%,并从先前的疲软中恢复过来。上个月,去年大幅增长了237%。
Even after such a large jump in price, MiMedx Group's price-to-sales (or "P/S") ratio of 3.4x might still make it look like a strong buy right now compared to the wider Biotechs industry in the United States, where around half of the companies have P/S ratios above 11.6x and even P/S above 49x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the highly reduced P/S.
即使在价格大幅上涨之后,与整个美国生物技术行业相比,MimedX Group的3.4倍市盈率(或 “市盈率”)仍可能使其目前看起来像是一个强劲的买盘。在美国,大约有一半的公司的市盈率超过11.6倍,甚至市盈率也高于49倍也很常见。尽管如此,我们需要更深入地挖掘以确定市盈率大幅下降是否有合理的基础。
View our latest analysis for MiMedx Group
查看我们对MimeDx集团的最新分析
NasdaqCM:MDXG Price to Sales Ratio vs Industry December 20th 2023
纳斯达克CM: MDXG 市销比率与行业对比 2023 年 12 月 20 日
How Has MiMedx Group Performed Recently?
MimedX 集团最近的表现如何?
With revenue growth that's inferior to most other companies of late, MiMedx Group has been relatively sluggish. It seems that many are expecting the uninspiring revenue performance to persist, which has repressed the growth of the P/S ratio. If you still like the company, you'd be hoping revenue doesn't get any worse and that you could pick up some stock while it's out of favour.
由于最近收入增长不如大多数其他公司,MimedX Group一直相对缓慢。似乎许多人预计平淡无奇的收入表现将持续下去,这抑制了市盈率的增长。如果你还喜欢这家公司,你会希望收入不会变得更糟,希望你能在它失宠的时候买入一些股票。
Keen to find out how analysts think MiMedx Group's future stacks up against the industry? In that case, our free report is a great place to start.
想了解分析师如何看待MimedX集团的未来与行业背道而驰吗?在这种情况下,我们的免费报告是一个不错的起点。
What Are Revenue Growth Metrics Telling Us About The Low P/S?
收入增长指标告诉我们什么是低市盈率?
There's an inherent assumption that a company should far underperform the industry for P/S ratios like MiMedx Group's to be considered reasonable.
有一种固有的假设是,如果像MimedX集团这样的市盈率被认为是合理的,一家公司的表现应该远远低于该行业。
Retrospectively, the last year delivered an exceptional 18% gain to the company's top line. Revenue has also lifted 21% in aggregate from three years ago, mostly thanks to the last 12 months of growth. Accordingly, shareholders would have probably been satisfied with the medium-term rates of revenue growth.
回顾过去,去年该公司的收入实现了惊人的18%增长。总收入也比三年前增长了21%,这主要归功于过去12个月的增长。因此,股东可能会对中期收入增长率感到满意。
Shifting to the future, estimates from the five analysts covering the company suggest revenue should grow by 12% per annum over the next three years. That's shaping up to be materially lower than the 235% per annum growth forecast for the broader industry.
展望未来,报道该公司的五位分析师的估计表明,未来三年收入将每年增长12%。这将大大低于整个行业每年235%的增长预期。
In light of this, it's understandable that MiMedx Group's P/S sits below the majority of other companies. Apparently many shareholders weren't comfortable holding on while the company is potentially eyeing a less prosperous future.
有鉴于此,可以理解的是,MimeDX集团的市盈率低于大多数其他公司。显然,当公司可能将目光投向不那么繁荣的未来时,许多股东并不愿意坚持下去。
The Final Word
最后一句话
Even after such a strong price move, MiMedx Group's P/S still trails the rest of the industry. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.
即使在价格走势如此强劲之后,MimedX Group的市盈率仍落后于业内其他公司。通常,在做出投资决策时,我们会谨慎行事,不要过多地解读市销比率,尽管这可以充分揭示其他市场参与者对公司的看法。
As expected, our analysis of MiMedx Group's analyst forecasts confirms that the company's underwhelming revenue outlook is a major contributor to its low P/S. Shareholders' pessimism on the revenue prospects for the company seems to be the main contributor to the depressed P/S. The company will need a change of fortune to justify the P/S rising higher in the future.
正如预期的那样,我们对MimedX Group分析师预测的分析证实,该公司令人沮丧的收入前景是其市盈率低的主要原因。股东对公司收入前景的悲观情绪似乎是市盈率低迷的主要因素。该公司需要改变命运才能证明未来市盈率上升是合理的。
We don't want to rain on the parade too much, but we did also find 1 warning sign for MiMedx Group that you need to be mindful of.
我们不想在游行队伍中下太多雨,但我们也为MimedX Group找到了一个需要注意的警告信号。
If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.
如果过去盈利增长稳健的公司处于困境,那么你可能希望看到这些盈利增长强劲、市盈率低的其他公司的免费集合。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧吗?请直接联系我们。或者,也可以发送电子邮件至编辑团队 (at) simplywallst.com。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。